New Investor Fact Sheet, page-21

Steady on KC. I’m not seeing a $1 party any time soon.

Going back to the Van Leeuwenhoeck report (link provided below), it’s final verdict after running the numbers was that POH’s fair sp value was approx. 8 - 9c. At the time it was written, the sp was 0.007.

The Van Leeuwenhoeck valuation was based only on POH’s opioid patch assets. If the figures were reworked, based on an assumption of $350 million peak sales for the oxymorphone patch, you would probably find that the 8-9c estimate would only increase by a couple of cents.

Personally, I think that would still undervalue the company, as the van Leeuwenhoeck estimate attributes no value to any of the other POH pipeline products, such as the TPM injectable pipeline.

BUT, as GC says, it’s all worth diddley- squat unless POH lands a deal.

http://www.phosphagenics.com/wp-con...search-Report-on-Phosphagenics-9-Feb-2016.pdf